Saniona, a clinical-stage biopharmaceutical company focused on rare diseases of the central nervous system, announced that it has regained exclusive, global rights to its GABAa5 negative allosteric modulator program from Boehringer Ingelheim, which has chosen to discontinue this collaboration for strategic reasons.
The termination of this collaboration provides Saniona with rights to a portfolio of more than 800 highly potent and selective compounds, which could be applicable in the treatment of various rare diseases.
Saniona previously entered into two drug discovery and development collaborations with Boehringer Ingelheim, both focused on research of small molecule therapeutics for schizophrenia. The first collaboration, initiated in 2016, was focused on GABAa5 negative allosteric modulators. The second collaboration, initiated in 2020, focuses on a novel, undisclosed CNS ion channel target, and it’s still ongoing.